Serum prostacyclin binding defects in thrombotic thrombocytopenic purpura
- PMID: 3880771
- PMCID: PMC423423
- DOI: 10.1172/JCI111670
Serum prostacyclin binding defects in thrombotic thrombocytopenic purpura
Abstract
To understand the pathophysiologic significance of abnormal serum prostacyclin (PGI2) binding activities in thrombotic thrombocytopenic purpura (TTP), we evaluated the PGI2 binding characteristics in three chronic TTP sera and 19 normal sera. PGI2 binding by serum was rapid and reversible. The binding activity in TTP sera (22.1 +/- SD, 4.4%) was significantly lower than that of normal sera (42.2 +/- 6.2%). Moreover, the antiaggregating activity and 6-keto-prostaglandin F1 alpha (6KPGF1 alpha) content in the gel filtrates representing the binding peak was proportionally lower in a TTP serum than normal serum. Although normal and TTP sera bound [14C]arachidonate with similar activity, and neither bound [3H]6KPGF1 alpha, there was a difference in prostaglandin E1 (PGE1) binding. Binding of [3H]PGE1 was subnormal in two TTP sera (W.J. and T.G.) and normal in the third (H.S.). Normal serum corrected the binding defects of TTP serum. Interestingly, the mixture of two TTP sera (W.J. and H.S.) mutually corrected their PGI2 binding defects. In addition, although in vivo plasma transfusions improved the PGI2 binding activity of W.J. and H.S., there existed a striking difference in the nature of their response. These observations indicate that there is at least two types of PGI2 binding defects in TTP. Our data indicate that TTP is associated with diminished serum binding of PGI2. This defect may reduce the availability of PGI2 to damaged vascular sites and decrease an important modulator of platelet thrombus formation at times of severe vascular insult.
Similar articles
-
Studies of the pathogenesis and management of thrombotic thrombocytopenic purpura.Pol J Pharmacol. 1996 Mar-Apr;48(2):179-84. Pol J Pharmacol. 1996. PMID: 9112648
-
Modulation of vascular thrombosis by products of arachidonic acid metabolism.Clin Physiol Biochem. 1984;2(2-3):84-90. Clin Physiol Biochem. 1984. PMID: 6435930 Review.
-
[Prostacyclin stability in thrombotic thrombocytopenic purpura. Japan Working Group on TTP].Nihon Rinsho. 1993 Jan;51(1):142-5. Nihon Rinsho. 1993. PMID: 8433507 Japanese.
-
Accelerated prostacyclin degradation in the thrombotic thrombocytopenic purpura.Lancet. 1981 Aug 8;2(8241):267-9. doi: 10.1016/s0140-6736(81)90522-5. Lancet. 1981. PMID: 6114320
-
Intravenous prostacyclin (as epoprostenol) infusion in thrombotic thrombocytopenic purpura. Four case reports and review of the literature. Italian Cooperative Group for Thrombotic Thrombocytopenic Purpura.Haematologica. 1994 Sep-Oct;79(5):429-37. Haematologica. 1994. PMID: 7843629 Review.
Cited by
-
Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I.J Clin Invest. 1988 Sep;82(3):803-7. doi: 10.1172/JCI113682. J Clin Invest. 1988. PMID: 3047170 Free PMC article.
-
Interaction between lymphocytes and platelets in the synthesis of prostacyclin.J Clin Invest. 1987 Jun;79(6):1601-6. doi: 10.1172/JCI112995. J Clin Invest. 1987. PMID: 3108319 Free PMC article.
-
Low-density lipoprotein promotes microvascular thrombosis by enhancing von Willebrand factor self-association.Blood. 2023 Sep 28;142(13):1156-1166. doi: 10.1182/blood.2023019749. Blood. 2023. PMID: 37506337 Free PMC article.
-
Glomerular fibrin deposition and removal.Pediatr Nephrol. 1990 Jan;4(1):78-87. doi: 10.1007/BF00858447. Pediatr Nephrol. 1990. PMID: 2206888 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources